amgen_hq

FDA approves first therapy for paediatric psoriasis treatment

November 7, 2016
Sales and Marketing Amgen, Enbrel, paediatric, psoriasis

Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. …

cmglee_cambridge_cancer_research_web

Cancer Research UK enters new oncology partnership

November 7, 2016
Sales and Marketing Cancer Research UK, TYG Oncology, oncology

Cancer Research UK (CRUK) and its commercial arm, Cancer Research Technology (CRT), haven entered into an agreement with TYG Oncology …

nestle_health_sciences

Nestle backs allergy biotech Aimmune to the tune of $145 million

November 7, 2016
Sales and Marketing Aimmune, allergy therapeutics, nestle

Nestle Health Science has invested $145 million in return for a 15% stake in Aimmune Therapeutics. Aimmune pursues food-allergy therapies …

Merck KGaA invests €250 million in production in China

November 4, 2016
Manufacturing and Production China, Merck KGaA, Nantong, manufacturing

Merck KGaA inaugurated their Nantong pharmaceutical plant on 4 November. At the same time, Merck also announced that it plans …

top_ten_1

Top Ten articles in the pharma industry this week

November 4, 2016
Medical Communications November, news, pharmaceutical, top 10, top ten, top ten stories

This week has seen pharmaceutical companies release their third quarter profits, good news for some whilst others have attempted to …

shutterstock_138095450

Sanofi, Lilly & Novo accused of pricing collusion

November 4, 2016
Manufacturing and Production, Medical Communications, Sales and Marketing

Bernie Sanders has continued his assault on pharma pricing after calling out Eli Lilly earlier this week by implicating Lilly, …

Lonza grows manufacturing capability by opening further site

November 4, 2016
Medical Communications Lonza, drug product services, manufacturing

Lonza, a Swiss multinational chemical and biotechnology company, has opened a new manufacturing facility in Basel, where their headquarters is …

astrazeneca_building_white

AstraZeneca’s post-heart attack drug gets NICE recommendation

November 4, 2016
Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack

AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …

Blood cancer sufferers to receive early access to BMS’ Opdivo

November 3, 2016
Medical Communications Bristol-Myers Squibb, lyphoma, opdivo

Bristol-Myers Squibb has announced that their immunotherapy drug, Opdivo (nivolumab), will be made available to patients in the UK through …

clinical_trials

Clinical trials and their patients: The rising costs and how to stem the loss

November 3, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials

The pharmaceutical industry has a big problem and it’s one that keeps getting worse every year – how to stop …

nice_reception

NICE approves first new drug for breast cancer in a decade

November 3, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

NICE has approved Eisai’s Halaven (eribulin) for routine treatment of sufferers of locally advanced or metastatic breast cancer that has …

bernie_2

Lily increases diabetes drug by 700% over 20 years

November 3, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernie Sanders, Eli Lily, Humalog, diabetes

It has come to light that, over a 20 year period, Eli Lily has increased the price of its diabetes …

merck_and_co

MSD’s Alzheimer’s study could break new ground for treatment

November 3, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, MSD, clinical trials

MSD, known as Merck in North America, has published results of a Phase I trial of verubecestat. The drug is …

fda2outsideweb

FDA issues warning letter after Chinese firm impedes investigation

November 2, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, FDA

The US Food and Drugs Administration (FDA) has issued a Chinese firm with a warning letter after claims it intentionally …

gilead-sciences

Gilead quietly drops drugs from line up alongide Q3 results

November 2, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abzena, Gilead, research and development

Gilead Sciences followed Pfizer in discreetly dropping a drug alongside its third quarter profit reports. The drug in question, for …

Multi Packaging Solutions wins ‘Packaging Company of the Year’

November 2, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Multi Packaging Solutions (“MPS”)(NYSE: MPSX),  a global market leader in healthcare, spirits, confectionery and media packaging, has been voted the …

Avacta joins major US cancer centre for CAR-T immunotherapy development

November 2, 2016
Research and Development Avacta, Memorial Sloan Kettering Cancer Center

Biotherapeutic and research reagent developer Avacta has announced it will collaborate with New York’s Memorial Sloan Kettering Cancer Center (MSK, …

gilead-sciences

Nimbus Therapeutics receives $200 million payment from Gilead

November 2, 2016
Research and Development Gilead Sciences, Nimbus Therapeutics, nash

Nimbus Therapeutics only signed a deal with Gilead Sciences back in April of this year and yet have already received …

ibm_web

Celgene partners with IBM for new pharmacovigilance platform

November 2, 2016
Research and Development, Sales and Marketing Celgene, Watson, ibm

IBM is set to join forces with Celgene to develop a new drug safety evaluation platform, it has emerged. Running …

valeant

Valeant looking at selling core asset to manage debt

November 2, 2016
Research and Development Takeda Pharmaceutical, Valeant pharmaceutical, salix

Valeant is rumoured to be looking into selling its Salix drugs business to Takeda Pharmaceutical, with figures floated of a …

The Gateway to Local Adoption Series

Latest content